International law firm Bird & Bird has advised long term client Precision for Medicine, part of the Precision Medicine Group, on its acquisition of Swiss company SimplicityBio from its founders.
The acquisition allows Precision to add artificial intelligence to its QuartzBio (TM) multi-omics data integration and computing platform. With this expansion, Precision will offer one of the most stable and sophisticated end-to-end solutions to meet the "big data" challenge of biomarker-driven drug discoveries.
Biomarkers are increasingly at the forefront of precision medicine and are critical to predicting and understanding clinical outcomes in a variety of treatments and populations. This biomarker data presents a major challenge in terms of complex data streams from multiple laboratories to different types of assays. The combination of QuartzBio and SimplicityBio allows companies to capture, for the first time, their complete (ex: genomic, transcriptomic, proteomic, flow cytometry) multi-omics data in Real-time access to make data-driven decisions in the context of different studies.
This transaction is an example of Bird & Bird's well-known technological focus gaining wide acceptance in the legal advisory market for M & A topics. Clients rely on Bird & Bird's know how and expertise in innovative digital business models and technology-focused industry expertise, including the AI and Big Data segments of the life sciences sector.
The Precision Medicine Group was led by Bird & Bird Corporate Partner Stefan Münch, who was assisted by Associate Inga Kerner (Corporate / M & A), Partner Dr. Christopher Maierhöfer and Associate Dominic Igel (both IP / Patent Law) all from Munich.